RGD1562043 Inhibitors
In the realm of putative RGD1562043 inhibitors, the focus rests heavily on key regulatory pathways, with the selected chemicals aiming to exert influence via these circuits. The class of inhibitors herein spans different functional classes from kinase inhibitors like INK-128 and WZ4003 to enzyme modulators like DAPT. Such chemicals provide a broad spectrum of inhibitory activity, affecting multiple steps in various pathways that may interact with or modulate RGD1562043. The AMPK AICAR, for example, would be instrumental in RGD1562043 if the protein were to be involved in cellular energy homeostasis.
Simultaneously, compounds like BAY 11-7082 and GW2580 manifest their activity by inhibiting inflammation and immune responses, targeting NF-κB and CSF1R, respectively. If RGD1562043 operates within such contexts, the compounds can effectively serve as indirect inhibitors. Specificity is inherent in how these chemicals are designed; for instance, ZM-447439 targets Aurora kinases, affecting cell cycle progression, and could inhibit RGD1562043 if it is implicated in cell cycle regulation. Collectively, the inhibitors offer a multi-faceted approach to disrupting the various pathways where RGD1562043 could operate.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Targets AMP-activated protein kinase (AMPK), a master regulator of cellular energy. Can inhibit RGD1562043 if the latter participates in energy regulation. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
Specifically inhibits mTORC1/2 complexes, affecting protein synthesis and autophagy. Can inhibit RGD1562043 if it interacts with the mTOR complexes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Specifically inhibits the activation of NF-κB by blocking the phosphorylation of IκBα. Can inhibit RGD1562043 if it is a downstream target of NF-κB. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
Akt inhibitor that affects downstream proteins involved in cell survival and apoptosis. Can inhibit RGD1562043 if it is in the Akt pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Specifically binds to FKBP12 and forms a complex with mTOR, inhibiting its activity. Can inhibit RGD1562043 if it is regulated by mTOR. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor that directly binds to the ATP-binding pocket of Aurora A and B. Can inhibit RGD1562043 if it is associated with Aurora kinases. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
γ-secretase inhibitor that blocks proteolytic cleavages of Notch, affecting cell fate decisions. Can inhibit RGD1562043 if it's involved in Notch signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK1 and ROCK2 kinases, impacting cytoskeletal dynamics. Can inhibit RGD1562043 if it affects cell morphology. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that competes with ATP for binding to JNK. Can inhibit RGD1562043 if it is part of the JNK signaling pathway. | ||||||
cFMS Receptor Tyrosine Kinase Inhibitor | 870483-87-7 | sc-203877 sc-203877A | 1 mg 5 mg | $32.00 $54.00 | ||
Targets CSF1R kinase, inhibiting macrophage survival. Can inhibit RGD1562043 if it has roles in immune cell survival. | ||||||